New approach to active immunotherapy of Hepatitis C related cancer

Project Details


Project goal is to develop a prototype active immunotherapy to complement directly acting antiviral drugs in treatment of chronic hepatitis C, which would target and eliminate HCV-infected cells, specifically malignant (transformed) hepatocytes and lymphocytes. The immunotherapy will be based on a conserved HCV antigen nucleocapsid (Core) protein and tumor-associated antigen involved in the early events in hepatocarcinogenesis, human telomerase reverse transcriptase, presented by synthetic genes (HCV/TERT-DNA).
Effective start/end date1/12/1828/02/21


  • Latvian Council of Science: €200,000.00


  • hepatitis C
  • hepatocellular carcinoma
  • non-Hodgkin's B-cell lymphoma
  • DNA vaccine
  • TLR ligand
  • checkpoint inhibitor
  • mouse model

Field of Science

  • 3.3 Health sciences

Smart Specialization Area

  • Biomedicine, medical technologies and biotechnology


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.